

October 12, 2026

## NEW TEST–UGT1A1 Genotyping

Effective Date: October 13, 2026

Test Name: UGT1A1 Genotyping

New Test Code: IRIN1

Current Test Code to be Discontinued: IRINT

**What you need to know:** Effective October 13, 2026, HNL Lab Medicine will offer a new UGT1A1 Genotyping test using test code IRIN1. The test will be orderable in Epic for LVH and LVPG providers. Once IRIN1 is available, the current IRINT send-out test code should no longer be used.

### Ordering Requirements

Beginning October 13, 2026, LVH/LVPG providers should order UGT1A1 Genotyping using test code IRIN1 in Epic. The previous IRINT send-out test code should no longer be used.

All orders require the following “**Answer on Order**” questions to be completed to document medical necessity:

- 1. I certify that the test I am ordering is medically necessary for the diagnosis and/or treatment of my patient, as documented in the patient’s medical record.**  
**Response:** Acknowledge
- 2. I confirm that the patient has a malignant neoplasm, treatment with a drug that is metabolized by UGT1A1 (such as irinotecan) is being considered, and UGT1A1 testing is necessary to prevent adverse drug-gene interactions.**  
**Response:** Acknowledge
- 3. Has this patient previously been tested for UGT1A1 genetic variants by HNL Lab Medicine or another laboratory?**  
**Response:** Yes/No

### Test Information

|                     |                                                                |
|---------------------|----------------------------------------------------------------|
| Test Name           | UGT1A1 Genotyping                                              |
| Alternate Name      | UDP Glucuronosyltransferase 1A1 (UGT1A1) Genotyping            |
| Test Code           | IRIN1                                                          |
| CPT Code            | 81350                                                          |
| Methodology         | Polymerase Chain Reaction (PCR)/Capillary Electrophoresis (CE) |
| Testing Schedule    | Routine, Monday–Friday, excluding holidays                     |
| Report Availability | 4–7 days                                                       |

### Specimen Requirements

|                         |                                                           |
|-------------------------|-----------------------------------------------------------|
| Specimen                | Whole blood                                               |
| Container               | Lavender Top (EDTA)                                       |
| Minimum Volume          | 1 mL                                                      |
| Collection Instructions | Immediately after collection, invert the tube 8–10 times. |

## Clinical Utility

The UGT1A1 Genotyping Assay is designed to support healthcare professionals in pharmacogenomic-guided medication management. Detection of UGT1A1 promoter TA repeat alleles may help identify patients at increased risk for irinotecan-associated toxicity and provide information to support individualized treatment and dosing decisions.

## Additional Information

For detailed test information, including specimen requirements, methodology, and ordering instructions, please refer to the HNL Lab Medicine [Test Directory](#).

If you have questions regarding this test, please contact HNL Lab Medicine Technical Support at 877-402-4221.

## Compliance Reminder

Tests and profiles must be ordered based on the individual patient's clinical needs. All testing must be reasonable and medically necessary, consistent with applicable coverage policies, and supported by documentation in the patient's medical record. Per [CFR 45 § 164.506](#), progress notes may be requested to support the test order or claim. For guidance on applicable coverage policies and medical necessity requirements, please refer to the [Medicare Resources Page](#).